β-Glucan-modified nanoparticles with different particle sizes exhibit different lymphatic targeting efficiencies and adjuvant effects.
10.1016/j.jpha.2024.02.007
- Author:
Wen GUO
1
;
Xinyue ZHANG
1
;
Long WAN
2
;
Zhiqi WANG
1
;
Meiqi HAN
3
;
Ziwei YAN
1
;
Jia LI
1
;
Ruizhu DENG
1
;
Shenglong LI
4
;
Yuling MAO
1
;
Siling WANG
1
Author Information
1. Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province 110016, China.
2. Department of Pharmacy, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang 110001, Liaoning, China.
3. Department of Microbiology and Biochemical Pharmacy, School of Medical Devices, Shenyang Pharmaceutical University, Shenyang 110016, China.
4. Second Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, 110042 Shenyang, PR China.
- Publication Type:Journal Article
- Keywords:
Dendritic cells mature;
Immunomodulatory nano-vaccine;
Lymph node targeting;
Mesoporous silica nanoparticles;
Smart nanoparticles
- From:
Journal of Pharmaceutical Analysis
2024;14(12):100953-100953
- CountryChina
- Language:English
-
Abstract:
Particle size and surface properties are crucial for lymphatic drainage (LN), dendritic cell (DC) uptake, DC maturation, and antigen cross-presentation induced by nanovaccine injection, which lead to an effective cell-mediated immune response. However, the manner in which the particle size and surface properties of vaccine carriers such as mesoporous silica nanoparticles (MSNs) affect this immune response is unknown. We prepared 50, 100, and 200 nm of MSNs that adsorbed ovalbumin antigen (OVA) while modifying β-glucan to enhance immunogenicity. The results revealed that these MSNs with different particle sizes were just as efficient in vitro, and MSNs with β-glucan modification demonstrated higher efficacy. However, the in vivo results indicated that MSNs with smaller particle sizes have stronger lymphatic targeting efficiency and a greater ability to promote the maturation of DCs. The results also indicate that β-glucan-modified MSN, with a particle size of ∼100 nm, has a great potential as a vaccine delivery vehicle and immune adjuvant and offers a novel approach for the delivery of multiple therapeutic agents that target other lymph-mediated diseases.
